86 related articles for article (PubMed ID: 26463707)
1. New Life for Immunotoxin Cancer Therapy.
Hassan R; Alewine C; Pastan I
Clin Cancer Res; 2016 Mar; 22(5):1055-8. PubMed ID: 26463707
[TBL] [Abstract][Full Text] [Related]
2. An immunotoxin targeting the gH glycoprotein of KSHV for selective killing of cells in the lytic phase of infection.
Cai Y; Berger EA
Antiviral Res; 2011 Jun; 90(3):143-50. PubMed ID: 21440007
[TBL] [Abstract][Full Text] [Related]
3. Recent advances with Treg depleting fusion protein toxins for cancer immunotherapy.
Kumar P; Kumar A; Parveen S; Murphy JR; Bishai W
Immunotherapy; 2019 Sep; 11(13):1117-1128. PubMed ID: 31361167
[TBL] [Abstract][Full Text] [Related]
4. Pentostatin plus cyclophosphamide safely and effectively prevents immunotoxin immunogenicity in murine hosts.
Mossoba ME; Onda M; Taylor J; Massey PR; Treadwell S; Sharon E; Hassan R; Pastan I; Fowler DH
Clin Cancer Res; 2011 Jun; 17(11):3697-705. PubMed ID: 21521777
[TBL] [Abstract][Full Text] [Related]
5. Advances in anticancer immunotoxin therapy.
Alewine C; Hassan R; Pastan I
Oncologist; 2015 Feb; 20(2):176-85. PubMed ID: 25561510
[TBL] [Abstract][Full Text] [Related]
6. Elimination of murine and human T-cell epitopes in recombinant immunotoxin eliminates neutralizing and anti-drug antibodies in vivo.
Mazor R; Crown D; Addissie S; Jang Y; Kaplan G; Pastan I
Cell Mol Immunol; 2017 May; 14(5):432-442. PubMed ID: 26477977
[TBL] [Abstract][Full Text] [Related]
7. A bivalent recombinant immunotoxin with high potency against tumors with EGFR and EGFRvIII expression.
Meng J; Liu Y; Gao S; Lin S; Gu X; Pomper MG; Wang PC; Shan L
Cancer Biol Ther; 2015; 16(12):1764-74. PubMed ID: 26467217
[TBL] [Abstract][Full Text] [Related]
8. Tofacitinib to prevent anti-drug antibody formation against LMB-100 immunotoxin in patients with advanced mesothelin-expressing cancers.
Skorupan N; Peer CJ; Zhang X; Choo-Wosoba H; Ahmad MI; Lee MJ; Rastogi S; Sato N; Yu Y; Pegna GJ; Steinberg SM; Kalsi SS; Cao L; Figg WD; Trepel JB; Pastan I; FitzGerald D; Alewine C
Front Oncol; 2024; 14():1386190. PubMed ID: 38706610
[TBL] [Abstract][Full Text] [Related]
9. Current therapeutic modalities and chemopreventive role of natural products in liver cancer: Progress and promise.
Singh AK; Singh SV; Kumar R; Kumar S; Senapati S; Pandey AK
World J Hepatol; 2023 Jan; 15(1):1-18. PubMed ID: 36744169
[TBL] [Abstract][Full Text] [Related]
10. Targeting the IL4 receptor with MDNA55 in patients with recurrent glioblastoma: Results of a phase IIb trial.
Sampson JH; Singh Achrol A; Aghi MK; Bankiewicz K; Bexon M; Brem S; Brenner A; Chandhasin C; Chowdhary S; Coello M; Ellingson BM; Floyd JR; Han S; Kesari S; Mardor Y; Merchant F; Merchant N; Randazzo D; Vogelbaum M; Vrionis F; Wembacher-Schroeder E; Zabek M; Butowski N
Neuro Oncol; 2023 Jun; 25(6):1085-1097. PubMed ID: 36640127
[TBL] [Abstract][Full Text] [Related]
11. Bacteria-derived chimeric toxins as potential anticancer agents.
Khoshnood S; Fathizadeh H; Neamati F; Negahdari B; Baindara P; Abdullah MA; Haddadi MH
Front Oncol; 2022; 12():953678. PubMed ID: 36158673
[TBL] [Abstract][Full Text] [Related]
12. Characterization of Mesothelin Glycosylation in Pancreatic Cancer: Decreased Core Fucosylated Glycoforms in Pancreatic Cancer Patients' Sera.
Duran A; Guerrero PE; Ortiz MR; Pérez Del Campo D; Castro E; Garcia-Velasco A; Fort E; de Llorens R; Saldova R; Llop E; Peracaula R
Biomedicines; 2022 Aug; 10(8):. PubMed ID: 36009489
[TBL] [Abstract][Full Text] [Related]
13. Transient Inhibition of Trastuzumab-Tumor Binding to Overcome the "Binding-Site Barrier" and Improve the Efficacy of a Trastuzumab-Gelonin Immunotoxin.
Chen P; Bordeau BM; Zhang Y; Balthasar JP
Mol Cancer Ther; 2022 Oct; 21(10):1573-1582. PubMed ID: 35930739
[TBL] [Abstract][Full Text] [Related]
14. Strategies to mitigate the on- and off-target toxicities of recombinant immunotoxins: an antibody engineering perspective.
Li M; Mei S; Yang Y; Shen Y; Chen L
Antib Ther; 2022 Jul; 5(3):164-176. PubMed ID: 35928456
[TBL] [Abstract][Full Text] [Related]
15. Overcoming Therapy Resistance and Relapse in TNBC: Emerging Technologies to Target Breast Cancer-Associated Fibroblasts.
Mollah F; Varamini P
Biomedicines; 2021 Dec; 9(12):. PubMed ID: 34944738
[TBL] [Abstract][Full Text] [Related]
16. DT389-YP7, a Recombinant Immunotoxin against Glypican-3 That Inhibits Hepatocellular Cancer Cells: An In Vitro Study.
Hashemi Yeganeh H; Heiat M; Kieliszek M; Alavian SM; Rezaie E
Toxins (Basel); 2021 Oct; 13(11):. PubMed ID: 34822533
[TBL] [Abstract][Full Text] [Related]
17. Small extracellular vesicles in cancer.
Abhange K; Makler A; Wen Y; Ramnauth N; Mao W; Asghar W; Wan Y
Bioact Mater; 2021 Nov; 6(11):3705-3743. PubMed ID: 33898874
[TBL] [Abstract][Full Text] [Related]
18. New Therapeutic Options for Advanced Hepatocellular Carcinoma.
Ma YS; Liu JB; Wu TM; Fu D
Cancer Control; 2020; 27(3):1073274820945975. PubMed ID: 32799550
[TBL] [Abstract][Full Text] [Related]
19. Combination of Detoxified Pneumolysin Derivative ΔA146Ply and Berbamine as a Treatment Approach for Breast Cancer.
Zhang H; Zhu T; Fu R; Peng Y; Jing P; Xu W; Wang H; Li S; Shu Z; Yin Y; Zhang X
Mol Ther Oncolytics; 2020 Sep; 18():247-261. PubMed ID: 32728613
[TBL] [Abstract][Full Text] [Related]
20. Enhanced efficacy of mesothelin-targeted immunotoxin LMB-100 and anti-PD-1 antibody in patients with mesothelioma and mouse tumor models.
Jiang Q; Ghafoor A; Mian I; Rathkey D; Thomas A; Alewine C; Sengupta M; Ahlman MA; Zhang J; Morrow B; Steinberg SM; Pastan I; Hassan R
Sci Transl Med; 2020 Jul; 12(550):. PubMed ID: 32611684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
